| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 64, 1320-1322, Copyright © 1987 by Endocrine Society
ARTICLES |
L Kennedy, AI Traub, AB Atkinson and B Sheridan
A GnRH superagonist, buserelin, was administered for 16 days to a postmenopausal woman with a testosterone-secreting ovarian tumor. Serum gonadotropin levels decreased by more than 70%, and serum testosterone fell by more than 50%. This short term study demonstrates that in these uncommon tumors androgen secretion is gonadotropin sensitive, and suggests that GnRH analogs may have therapeutic value in such patients.
This article has been cited by other articles:
![]() |
R.T. Netea-Maier, W.-A. Nieuwlaat, C.G.J. Sweep, P. Wesseling, L. Massuger, and A.R.M.M. Hermus Virilization due to ovarian androgen hypersecretion in a patient with ectopic adrenocorticotrophic hormone secretion caused by a carcinoid tumour: Case Report Hum. Reprod., October 1, 2006; 21(10): 2601 - 2605. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. B. Barnes and D. A. Ehrmann Long-Term Suppression of Testosterone After Treatment with a Gonadotropin-Releasing Hormone Agonist in a Woman with a Presumed Testosterone Secreting Ovarian Tumor J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1746 - 1748. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |